BioCryst Pharmaceuticals, Inc.

577 articles about BioCryst Pharmaceuticals, Inc.

• Biocryst Pharmaceuticals Initiates Intravenous Phase I/II Clinical Trial Of Fodosine(TM) In Patients With B-Cell Acute Lymphoblastic Leukemia

  12/22/2005

• Biocryst Pharmaceuticals Announces Early Termination Of Hart-Scott-Rodino Waiting Period For The Roche License Of BCX-4208

  12/22/2005

• Biocryst Pharmaceuticals And Roche Licensing Deal Wins Early Approval From FTC

  12/22/2005

• Biocryst Pharmaceuticals Completes $30.0 Million Common Stock Offering To Institutional Investors

  12/19/2005

• Biocryst Pharmaceuticals Announces $30.0 Million Common Stock Offering To Institutional Investors

  12/15/2005

• Biocryst Pharmaceuticals Announces Presentation Of Fodosine(TM) Data During The 47th Annual Meeting And Exposition Of The American Society of Hematology

  12/12/2005

• Biocryst Pharmaceuticals To Provide Summary Of Data Presented At The 47th Annual Meeting And Exposition Of The American Society of Hematology

  12/7/2005

• Roche And Biocryst Pharmaceuticals Collaborate On Clinical Compound BCX-4208 For Transplantation And Autoimmune Diseases; Agreement Worth Up To $530 Million

  11/30/2005

• Biocryst Pharmaceuticals To Present At The Lazard Capital Markets Annual Life Sciences Conference

  11/28/2005

• Biocryst Pharmaceuticals Files IND Application For Injectable Peramivir

  11/28/2005

• Biocryst Pharmaceuticals Announces Publication Of Abstracts On Fodosine(TM) And Presentation At The 47th Annual Meeting And Exposition Of The American Society of Hematology

  11/17/2005

• Biocryst Pharmaceuticals To Present At The Rodman & Renshaw Techvest 7th Annual Healthcare Conference

  11/2/2005

• Biocryst Pharmaceuticals Reports Third Quarter 2005 Financial Results

  10/26/2005

• AMEX To Trade Options On Biocryst Pharmaceuticals

  10/26/2005

• Biocryst Pharmaceuticals To Release Third Quarter 2005 Financial Results On Wednesday, October 26, 2005; Conference

  10/20/2005

• Biocryst Pharmaceuticals To Present At The Bear Stearns 18th Annual Healthcare Conference

  9/7/2005

• Biocryst Pharmaceuticals Assigns Certain Rights From Complement Research To 3-Dimensional Pharmaceuticals, Inc.

  12/23/2003